melanoma

[Bioengineered] Downregulation of sperm-associated antigen 5 repressed malignant melanoma cell growth and epithelial to mesenchymal transition, which might be induced by inactivation of the forkhead box protein M1/A disintegrin and metalloproteinase 17/NOTCH1 signaling.

[Current Oncology Reports] The authors examine the potential role of circulating tumor DNA as a clinical tool to inform clinical decision-making from early to late stage cutaneous melanoma.

[Expert Opinion On Biological Therapy] The authors describe the mechanisms of immune checkpoint activation and inhibition, second, andsummarize the results obtained with immune checkpoint inhibitorin melanoma treatment in terms of efficacy.

[Cancer Gene Therapy] Scientists observed the elevated expression of chemokine receptor 4 (CXCR4) in uveal melanoma (UM) patient liver tissues, and high CXCR4 expression in liver metastases of UM murine models, regardless of the expression levels in the primary tumors.

[NeoImmuneTech, Inc. (Businesswire, Inc.)] NeoImmuneTech, Inc. announced that the first patient has been dosed in the Phase IIa portion of a study evaluating NT-I7, a novel long-acting human interleukin-7, in combination with the PD-L1 targeting drug atezolizumab, in patients with advanced high-risk skin cancers including melanoma, merkel cell carcinoma, and cutaneous squamous cell carcinoma.

[Proceedings of the National Academy of Sciences of the United States of America] Glucose 6-phosphate dehydrogenase (G6PD) mutant melanomas had significantly decreased G6PD enzymatic activity and depletion of intermediates in the oxidative pentose phosphate pathway.